source
- Attovia Therapeutics raises $289 million in IPO to fund antibody-drug research for skin and inflammatory diseasesAttovia Therapeutics completed an IPO raising $289 million, selling 17 million shares at $17 each and valuing the company at $767 million. Shares will begin trading on Nasdaq under the ticker ATTO.…
- Novo Nordisk looks to bolt-on acquisitions as pipeline setbacks mountNovo Nordisk CEO Maziar Mike Doustdar said on a media call that the pharma industry is tough for those who dislike setbacks and failure. He highlighted recent disappointments in the company's pipe…